UY24654A1 - Composición de vacuna contra la malaria - Google Patents

Composición de vacuna contra la malaria

Info

Publication number
UY24654A1
UY24654A1 UY24654A UY24654A UY24654A1 UY 24654 A1 UY24654 A1 UY 24654A1 UY 24654 A UY24654 A UY 24654A UY 24654 A UY24654 A UY 24654A UY 24654 A1 UY24654 A1 UY 24654A1
Authority
UY
Uruguay
Prior art keywords
composition
vaccine against
against malaria
malaria
adjuvant
Prior art date
Application number
UY24654A
Other languages
English (en)
Inventor
Joseph Cohen
Original Assignee
Smithkline Beecham Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog
Publication of UY24654A1 publication Critical patent/UY24654A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una composición de vacuna útil para la prevención o tratamiento de la malaria que comprende varios antígenos derivados de la malaria en combinación con un adyuvante que es un estimulador preferencial de la célula TH1.
UY24654A 1996-08-02 1997-08-01 Composición de vacuna contra la malaria UY24654A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9616351.4A GB9616351D0 (en) 1996-08-02 1996-08-02 Vaccine composition

Publications (1)

Publication Number Publication Date
UY24654A1 true UY24654A1 (es) 2001-08-27

Family

ID=10797980

Family Applications (1)

Application Number Title Priority Date Filing Date
UY24654A UY24654A1 (es) 1996-08-02 1997-08-01 Composición de vacuna contra la malaria

Country Status (32)

Country Link
US (2) US20020172692A1 (es)
EP (2) EP0957933B1 (es)
JP (1) JP2000517295A (es)
KR (1) KR20000029747A (es)
CN (1) CN1241639C (es)
AP (1) AP1166A (es)
AR (1) AR008799A1 (es)
AT (1) ATE394119T1 (es)
AU (1) AU706303B2 (es)
BG (1) BG63290B1 (es)
BR (1) BR9710913A (es)
CA (1) CA2262402A1 (es)
CO (1) CO4650186A1 (es)
CZ (1) CZ290826B6 (es)
DE (1) DE69738672D1 (es)
DZ (1) DZ2283A1 (es)
EA (1) EA002167B1 (es)
GB (1) GB9616351D0 (es)
ID (1) ID17860A (es)
IL (1) IL128318A (es)
MA (1) MA24291A1 (es)
MY (1) MY116128A (es)
NO (1) NO319844B1 (es)
OA (1) OA10969A (es)
PE (1) PE97298A1 (es)
PL (1) PL188741B1 (es)
SK (1) SK282438B6 (es)
TR (1) TR199900195T2 (es)
UA (1) UA68336C2 (es)
UY (1) UY24654A1 (es)
WO (1) WO1998005355A1 (es)
ZA (1) ZA976815B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9915204D0 (en) * 1999-06-29 1999-09-01 Smithkline Beecham Biolog Vaccine
NZ539509A (en) 2002-10-23 2008-05-30 Glaxosmithkline Biolog Sa Priming vaccine comprising a polynucleotide encoding at least one first malarial antigen and a boosting vaccine comprising at least one polypeptide comprising at least one second malarial antigen having at least one epitope in common with the first malarial antigen of the priming vaccine
CA2549185C (en) * 2003-12-01 2012-10-30 Meiji Dairies Corporation Peptide inhibiting angiotensin converting enzyme
GB0513421D0 (en) 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
JP2009503051A (ja) * 2005-08-02 2009-01-29 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル 油含有アジュバントと界面活性剤含有アジュバントとの間の干渉の減少
AU2007276217B2 (en) 2006-07-18 2013-08-29 Glaxosmithkline Biologicals S.A. Vaccines for malaria
GB0614254D0 (en) * 2006-07-18 2006-08-30 Smithkline Beecham Biolog Vaccine
PL2097102T3 (pl) 2006-09-07 2012-10-31 Glaxosmithkline Biologicals Sa Szczepionka skojarzona o zmniejszonej ilości antygenu wirusa polio
KR20100068390A (ko) 2007-08-13 2010-06-23 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
JP2011507816A (ja) * 2007-12-21 2011-03-10 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム マラリア用ワクチン
CL2008003875A1 (es) * 2007-12-24 2010-02-05 Glaxosmithkline Biologicals Sa Particula proteínica inmunógena que comprende una proteína de fusión que comprende secuencias derivadas de una proteina cs de p. vivax y el antigeno s de la hepatitis b y el antigeno s derivado del virus de la hepatitis b; composicion farmaceutica que lo comprende; procedimiento de producción; y su uso para tratar malaria.
WO2010002818A2 (en) * 2008-06-30 2010-01-07 United States Army As Represented By The Secretar Of The Army Malaria vaccine of self-assembling polypeptide nanoparticles
CA2769996C (en) * 2009-11-05 2018-06-12 The United States Of America As Represented By The Secretary Of The Na Plasmodium falciparum sporozoite and liver stage antigens
WO2012041669A1 (en) 2010-09-27 2012-04-05 Crucell Holland B.V. Heterologous prime boost vaccination regimen against malaria
GB201116248D0 (en) 2011-09-20 2011-11-02 Glaxosmithkline Biolog Sa Liposome production using isopropanol
WO2013074501A1 (en) 2011-11-14 2013-05-23 Crucell Holland B.V. Heterologous prime-boost immunization using measles virus-based vaccines
US9169304B2 (en) 2012-05-01 2015-10-27 Pfenex Inc. Process for purifying recombinant Plasmodium falciparum circumsporozoite protein
CN104338129B (zh) * 2013-07-26 2017-05-24 中国科学院上海巴斯德研究所 雷帕霉素作为疫苗佐剂的用途及制备方法
CN110035770B (zh) 2016-12-07 2023-06-16 葛兰素史密丝克莱恩生物有限公司 新方法
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
IE87413B1 (en) 2017-05-30 2023-07-19 Glaxosmithkline Biologicals Sa Novel methods for manufacturing an adjuvant
MX2020005481A (es) 2017-12-01 2020-12-07 Glaxosmithkline Biologicals Sa Purificacion de saponina.
JP2022535091A (ja) 2019-06-05 2022-08-04 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サポニン精製

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0071705B1 (en) * 1981-05-21 1989-11-23 The Wellcome Foundation Limited Protozoal antigen
ES8800273A1 (es) * 1985-03-28 1987-11-01 Univ New York Perfeccionamientos en la fabricacion de conjugados de proteinas portadores de antigenos inmunogenicos para vacunas contra la malaria
GB8819209D0 (en) * 1988-08-12 1988-09-14 Research Corp Ltd Polypeptide & dna encoding same
GB9012580D0 (en) * 1990-06-06 1990-07-25 Univ Nijmegen Novel protein
FR2679776A1 (fr) * 1991-07-31 1993-02-05 Pasteur Institut Melange de constituants peptidiques ayant des proprietes vaccinantes contre le paludisme, notamment du a plasmodium falciparum.
SG48390A1 (en) * 1991-11-16 1998-04-17 Smithkline Beecham Biolog Hybrid protein between cs from plasmodium and hbs ag
US6169171B1 (en) * 1992-02-27 2001-01-02 Smithkline Beecham Biologicals (S.A.) Hybrid protein between CS from plasmodium and HBSAG
DK0671948T3 (da) * 1992-06-25 1997-09-01 Smithkline Beecham Biolog Vaccinepræparat indeholdende adjuvanser
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
AUPM368994A0 (en) * 1994-02-04 1994-02-24 Saramane Pty Ltd Malaria merozoite antigen subunit vaccine
FR2744723A1 (fr) * 1996-02-14 1997-08-14 Pasteur Institut Proteine recombinante contenant un fragment c-terminal d'une proteine msp-1 d'un plasmodium infectieux pour l'homme pour la production de vaccins anti-paludiques
FR2744724B1 (fr) * 1996-02-14 2002-08-02 Pasteur Institut Proteine recombinante contenant un fragment c-terminal de la proteine msp-1 d'un plasmodium infectieux pour l'homme pour la production de vaccins anti-paludiques

Also Published As

Publication number Publication date
CO4650186A1 (es) 1998-09-03
US20020172692A1 (en) 2002-11-21
IL128318A (en) 2002-04-21
WO1998005355A1 (en) 1998-02-12
AP9901448A0 (en) 1999-03-31
MA24291A1 (fr) 1998-04-01
CA2262402A1 (en) 1998-02-12
UA68336C2 (en) 2004-08-16
EA002167B1 (ru) 2002-02-28
DE69738672D1 (de) 2008-06-19
DZ2283A1 (fr) 2002-12-25
US20060292170A1 (en) 2006-12-28
NO990464D0 (no) 1999-02-01
PL188741B1 (pl) 2005-04-29
JP2000517295A (ja) 2000-12-26
CN1231613A (zh) 1999-10-13
EA199900069A1 (ru) 1999-10-28
EP0957933B1 (en) 2008-05-07
ID17860A (id) 1998-01-29
AU706303B2 (en) 1999-06-10
EP1623720A2 (en) 2006-02-08
AR008799A1 (es) 2000-02-23
BR9710913A (pt) 1999-08-17
IL128318A0 (en) 2000-01-31
OA10969A (en) 2003-03-04
KR20000029747A (ko) 2000-05-25
PL331424A1 (en) 1999-07-19
EP1623720A3 (en) 2006-02-22
CZ290826B6 (cs) 2002-10-16
PE97298A1 (es) 1999-02-14
AP1166A (en) 2003-06-30
EP0957933A1 (en) 1999-11-24
GB9616351D0 (en) 1996-09-11
ATE394119T1 (de) 2008-05-15
CZ29299A3 (cs) 1999-06-16
SK11599A3 (en) 2000-03-13
BG63290B1 (bg) 2001-09-28
NO990464L (no) 1999-02-01
AU4204097A (en) 1998-02-25
BG103141A (en) 1999-08-31
TR199900195T2 (xx) 1999-04-21
NO319844B1 (no) 2005-09-19
CN1241639C (zh) 2006-02-15
MY116128A (en) 2003-11-28
SK282438B6 (sk) 2002-02-05
ZA976815B (en) 1998-05-11

Similar Documents

Publication Publication Date Title
UY24654A1 (es) Composición de vacuna contra la malaria
NO982497D0 (no) Vaksine-sammensetninger for inntak gjennom nesen
ES2125630T3 (es) Dispositivo implantable que contiene celulas tumorales, para el tratamiento del cancer.
ES2140076T3 (es) Vacunas que contienen una saponina y un esterol.
PA8443001A1 (es) Prevencion de la perdida y restauracion de la masa osea por determinados agonistas de prostaglandinas
ES2098029T3 (es) Vacunas de hepatitis que contienen monofosforil lipido a 3-o-desacilado.
ES500916A0 (es) Un procedimiento para la preparacion y estabilizacion de una composicion blanqueante acuosa que contiene peroxido de hi-drogeno.
MY113428A (en) Hepatitis b vaccine
NO20056021L (no) Anvendelse av CS-866 til fremstilling av et medikament
ES2180541T3 (es) Nueva fosfolipasa a1, procedimiento para su preparacion y uso de la misma.
ATE329617T1 (de) Antigen enthaltende zusammensetzung, die zusätzlich derivatisierte monoglyceride oder diglyceride als adjuvantien enthält
PT90727A (pt) Processo para a preparacao de uma proteina possuindo um ou mais determinantes imuno-reactivos e/ou antigenicos de um antigenio de superficie eimeria e de vacinas contra a coccidiose que a contem
ATE284710T1 (de) Adjuvans für vitale impfstoffe
ES2164367T3 (es) Tratamiento superficial del metal.
BG102818A (en) D-manitol and method for its preparation
ES2170143T3 (es) Composiciones que comprenden halofantrina en una forma especial.
ATE220687T1 (de) Die erzeugung einer immunantwort gegen erwünschte determinanten
FI962550A (fi) Deuterisoidut vaikuttavat aineet transdermaalisessa käyttötarkoituksessa
AU1815899A (en) Method and composition to enhance the efficacy of a vaccine using chemokines
AR018321A1 (es) Una forma de dosificacion de liberacion prolongada que comprende oxibutinina y los usos de la oxibutinina y de la forma de dosificacion de liberacionprolongada.
UA32598C2 (uk) Спосіб одержання лікарської форми карбамазепіну
HUP9902885A1 (hu) Maláriaellenes vakcinakészítmények
IT1275436B (it) Uso della forskolina e di estratti che la contengono per il trattamento della alcol-dipendenza
MX9302142A (es) Uso de 3r- y 3r,s-difenilmetoxi-1-(3,4-metileno-dioxifenetil)-piperidina y composicion que la contienen.
GB9303681D0 (en) Vaccines

Legal Events

Date Code Title Description
VENC Patent expired

Effective date: 20170801